Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2890886 | 1.00 | TSHR (0.43) | TSHRACHECYP3A4TDP1CD44 | |
| Methyl Alcohol SCHEMBL28179894 | 0.95 | ACHE (0.39) | TSHRACHECYP3A4TDP1CD44 | |
| SCHEMBL29468607 | 0.79 | TSHR (0.47) | TSHRACHECYP3A4TDP1ALDH1A1 | |
| SCHEMBL235850 | 0.79 | TSHR (0.47) | TSHRACHECYP3A4TDP1ALDH1A1 | |
| SCHEMBL8999536 | 0.77 | TSHR (0.45) | TSHRACHECYP3A4TDP1ALDH1A1 | |
| SCHEMBL29726981 | 0.77 | TSHR (0.45) | TSHRACHECYP3A4TDP1ALDH1A1 | |
| SCHEMBL1642155 | 0.77 | TSHR (0.45) | TSHRACHECYP3A4TDP1ALDH1A1 | |
| SCHEMBL6508099 | 0.77 | TSHR (0.45) | TSHRACHECYP3A4TDP1ALDH1A1 | |
| SCHEMBL8666802 | 0.75 | TSHR (0.43) | TSHRACHECYP3A4TDP1ALDH1A1 | |
| SCHEMBL20774081 | 0.75 | TSHR (0.43) | TSHRACHECYP3A4TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107311887-B | A kind of method of visible identification chiral sulfenamide | 中国科学院化学研究所 | 2019-02-26 | — | — | CN | claimed |
| CN-108558714-A | A kind of chirality optical voidness is to the preparation method of toluenesulfinamide | 上海晋鲁医药科技有限公司 | 2018-09-21 | — | — | CN | claimed |
| CN-108484455-A | A kind of method of synthesis of chiral optical voidness to toluenesulfinamide | 上海晋鲁医药科技有限公司 | 2018-09-04 | — | — | CN | claimed |
| CN-108440349-A | A kind of chirality optical voidness is to the preparation method of toluenesulfinamide | 上海晋鲁医药科技有限公司 | 2018-08-24 | — | — | CN | claimed |
| CN-107311887-A | A kind of method of visible identification chiral sulfenamide | 中国科学院化学研究所 | 2017-11-03 | — | — | CN | claimed |
| EP-1756085-B1 | DIASTEREOSELECTIVE SYNTHESIS PROCESS WITH 6-BROMO-4-(3-CHLOROPHENYL)-2-METHOXY-QUINOLINE | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-16 | — | — | EP | claimed |
| US-20070254929-A1 | Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | WYETH (US) | 2007-11-01 | — | — | US | claimed |
| EP-1756085-A1 | DIASTEREOSELECTIVE SYNTHESIS PROCESS WITH 6-BROMO-4-(3-CHLOROPHENYL)-2-METHOXY-QUINOLINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-28 | — | — | EP | claimed |
| EP-1608638-A1 | FLUORO-AND TRIFLUOROALKYL-CONTAINING HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION AND DERIVATIVES THEREOF | Wyeth (US) | 2005-12-28 | — | — | EP | claimed |
| WO-2005105783-A1 | DIASTEREOSELECTIVE SYNTHESIS PROCESS WITH 6-BROMO-4-(3-CHLOROPHENYL)-2-METHOXY-QUINOLINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | WO | claimed |
| WO-2004092155-A1 | FLUORO-AND TRIFLUOROALKYL-CONTAINING HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION AND DERIVATIVES THEREOF | WYETH (US) | 2004-10-28 | — | — | WO | claimed |
| US-20040198778-A1 | Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | WYETH | 2004-10-07 | — | — | US | claimed |
| WO-2023239822-A1 | CO-AGENTS AS THERAPY AGAINST ANAEROBIC PATHOGENS | FLEURIR ABX LLC (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-3856341-A1 | CRYSTALLINE FORMS OF (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZINYL)-PYRIMIDIN-5-YL)ETHAN-1-AMINE AND METHODS OF MAKING | Blueprint Medicines Corporation (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020210669-A1 | CRYSTALLINE FORMS OF (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZINYL)-PYRIMIDIN-5-YL)ETHAN-1-AMINE AND METHODS OF MAKING | BLUEPRINT MEDICINES CORPORATION (US) | 2020-10-15 | — | — | WO | disclosed |
| CN-109776383-A | A kind of preparation method of 3- indoles aryl sulfoxid es class compound | 哈尔滨工业大学（威海） | 2019-05-21 | — | — | CN | disclosed |
| WO-2004092155-A1 | FLUORO-AND TRIFLUOROALKYL-CONTAINING HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION AND DERIVATIVES THEREOF | WYETH (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040198778-A1 | Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | WYETH | 2004-10-07 | — | — | US | disclosed |
| WO-2004026814-A2 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF TUBULIN INHIBITORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-2003091207-A2 | METHOD OF PREPARING AMINE STEREOISOMERS | APSINTERM, LLC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254929-A1 | Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | SCN8A, CHD8, CHRNA7 | TSHR 202/4885ACHE 806/4885CYP3A4 2849/4885 |
| US-20040198778-A1 | Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | BACE1, APP, PSEN1 | TSHR 835/4885ACHE 501/4885CYP3A4 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.